In the development of NAFLD, PPAR-γ can stimulate the expression of downstream FASN by regulating SREBP-1c [52], while SREBP-1c has the ability to upregulate the gene expression of de novo adipose synthase FASN and is a major regulator of hepatic lipogenesis [53]. Here, PPARG is linked to metabolic dysfunction-associated steatotic liver disease.